Avigen, Inc.

Avigen to raise $21.2 million in private placement of common stock

Published in Mental Health Law Weekly, June 3rd, 2006

Avigen, Inc., (AVGN) a biopharmaceutical company focused on unique small molecule therapeutics to treat chronic neurological conditions, has entered into agreements to raise approximately $21.2 million through a private placement of common stock with institutional investors.

The transaction, which is expected to close on or about May 15, 2006, involves the sale of approximately 3.9 million shares of common stock at a purchase price of $5.37 per share. Avigen intends to use the net proceeds from the placement to expand the scope of its planned development programs to pursue additional applications for its current neurologic compounds, including AV650, for the treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Law Weekly

Source: Mental Health Law Weekly (2006-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry